SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weak fourth-quarter outlook, citing PC-market softness and manufacturing constraints, overshadowed its quarterly results and prompted analyst downgrades, driving a sharp selloff. Traders are divided between calling the drop an overreaction and buying the dip, versus expecting further declines as the turnaround remains uncertain.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is drawing attention after shares sold off sharply despite a strong earnings beat, higher guidance and a planned 8-for-1 split, amid weakness across tech and memory stocks. Bulls call the drop an overreaction and point to AI-storage demand, while bears cite slowing growth and the risk that memory prices have peaked.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits sharp selloff followed a strong quarterly report but softer forward guidance, missed user-growth expectations, and managements warning that Google search referrals are declining; traders also worry that a planned logged-in experience could further limit traffic. The community is split between fears that AI-driven search changes and login restrictions threaten growth, and buyers who view the drop as an overreaction to a still-profitable business.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly earnings miss and heavy AI infrastructure spending, which drove concerns about cash flow and whether the investment will earn adequate returns, overshadowed accelerating AWS growth. Traders debated whether the selloff was overdone: many bought the dip and highlighted AWS, while others remained bearish over rising capex and uncertain AI payback; shares also staged a notable rebound.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is under pressure amid a broad tech selloff, as Amazons heavy AI spending and cash-burn concerns and Intels weak outlook intensify doubts about the payoff from AI investment. Traders are divided between expecting further downside and seeing the sharp decline as an oversold dip-buying opportunity.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas preliminary reimbursement outlook, which points to a significant decline in DefenCaths contribution after the first quarter of 2027, has raised concerns about CorMedixs sales outlook. Those worries are compounded by Fresenius real-world data showing no significant difference in infection outcomes versus ClearGuard; traders debate whether the findings threaten DefenCaths adoption or are too preliminary to undermine its case.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX is drawing attention after a sharp rally and breakout, with traders speculating about a possible buyout and short covering; some connect the takeover talk to Novartiss weaker BTK results, but no deal is confirmed. Others point to upcoming earnings and BRIUMVIs growth and subcutaneous-development prospects as reasons for optimism, while debating whether the move reflects fundamentals or takeover hopes.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor selloff, led by Intels weak outlook and concerns about PC demand and tech earnings, is driving attention to SOXL; the funds 3x leverage has amplified the decline. Traders are divided between expecting further losses and buying the dip, with some arguing the AI-chip growth outlook remains intact.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention after a sharp selloff alongside AI and optical-infrastructure stocks, with traders citing broader sector weakness and concerns about dilution, capital needs, and customer concentration rather than a clear company-specific catalyst. Bulls point to ongoing data-center optics demand and upcoming earnings, while bears worry the decline may continue.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is under pressure as weak Amazon and Intel resultsalong with concerns about the cost and payoff of AI spendingfed a broader tech-led selloff. Traders are divided between expecting further declines and looking for a technical bounce, with volatility and stop-outs prominent in the discussion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With CNS Pharmaceuticals Stock On Wednesday?

CNS Pharmaceuticals plans a pivot to an acquisition-led strategy, capital raise, and technicals signal momentum with caution.read more...

Best Small Cap Stocks To Keep An Eye On - May 4th

Direxion Daily MU Bull 2X Shares, Inflection Point Acquisition Corp. II, CNS Pharmaceuticals, Critical Metals, Elong Power, Direxion Daily PLTR Bear 1X Shares, and Spring Valley Acquisition are the seven Small Cap stocks to watch today, according to MarketBeat's stock screener tool. Small-cap stock...

Medical Stocks To Watch Today - May 4th

Arcellx, Eli Lilly and Company, UnitedHealth Group, CNS Pharmaceuticals, and Johnson & Johnson are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies involved in healthcare including pharmaceuticals, biotec...

Pharmaceutical Stocks To Follow Today - May 4th

Eli Lilly and Company, CNS Pharmaceuticals, Novo Nordisk A/S, Abbott Laboratories, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell...

Institutional Giants Are Piling into Four of These NASDAQ Plays

The market is currently seeing a flurry of activity as companies across the biotech and technology sectors secure substantial funding and execute strategic transformations. $CNSP, $KBLB, $PN, $RLYB, $ADVB, $CLNN, $CABA

Why Did CNSP Stock Surge 330% Today?

Equity

The company announced a private placement, involving the sale of 650,000 common shares at $2.30 each, along with pre-funded warrants tied to over 9.1 million shares.

Nano-Cap CNS Pharmaceuticals Stock Explodes As Capital Raise Fuels Pivot

CNS Pharmaceuticals announces $22.5 million financing as the company pivots its strategy, eyes asset acquisitions.read more...

CNS Pharmaceuticals Secures $22.5 M in Oversubscribed Private Placement

CNS Pharmaceuticals (NASDAQ:CNSP) significantly boosted its capital reserves, entering into securities purchase agreements for a private placement expected to generate $22.5 million in gross proceeds.

CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved

The company intends to commence the phase 2 study of its lead program, TPI 287, to treat Glioblastoma Multiforme (GBM) by year-end.

This account has been verified as an official CNSP representative.

Verified Account

CNS Pharma

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

Neutral Sentiment

<ul class="summary-bullets"><li>CNS Pharmaceuticals plans to use the proceeds, along with existing cash, to identify and acquire new drug candidates in neurology and oncology.</li><li>The company is looking to out-license its legacy programs, including Berubicin and TPI-287, to treat tumors.</li><li>The biotech firm will look to acquire or license preclinical and clinical-stage assets with clear development paths and strong commercial potential.</li></ul>Shares of CNS Pharmaceuticals Inc. (CNSP) rocketed over 330% in early trade on Monday, registering their biggest ever single-day gains since implementing a 1-for-12 reverse stock split last July, as investors cheered a $22.5 million private placement to boost its acquisition strategy.The financing includes participation from institutional healthcare investors such as ADAR1 Capital, Ikarian Capital, Stonepine Capital Management, and Nazare Partners.The private placement involves the sale of 650,000 common shares at $2.30 each, along with pre-funded warrants tied to over 9.1 million shares. CNSP shares closed at $2.31 on Friday.“With the proceeds from this financing, the company is now in a strong position to execute on our recently announced corporate strategy and capitalize on opportunities created by the dynamic biotech environment over the last several years,” said Rami Levin, President and CEO of CNS Pharmaceuticals.<h2 class="st-heading-2">Strategic Shift Toward Acquisitions, Licensing</h2>CNS Pharmaceuticals plans to use the proceeds, along with existing cash, to identify and acquire new drug candidates in neurology and oncology. The company is prioritizing assets with clear development paths, strong scientific backing, and near-term catalysts.At the same time, the firm is looking to out-license its legacy programs, including Berubicin and TPI-287, to treat tumors.In March, CNS Pharmaceuticals <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://cnspharma.com/cns-pharmaceuticals-launches-new-corporate-strategy-focused-on-building-a-high-value-neurology-and-oncology-pipeline/">announced</a> a new growth strategy focused on building a strong pipeline in neurology and oncology. The biotech firm will look to acquire or license preclinical and clinical-stage assets, prioritizing programs with clear development paths and strong commercial potential.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/CNSP">CNSP</a> on Stocktwits turned ‘extremely bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One user saw $11 to $12 as a key resistance level.<stembedurl>https://stocktwits.com/cjstocksup/message/652162741</stembedurl>However, another user expects the stock to drop “hard.”<stembedurl>https://stocktwits.com/belikemike7/message/652165417</stembedurl>The stock is up 70% year-to-date.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/why-xndu-stock-down-today-xanadu-quantum-share-registration/cZQMsDAReJ4">XNDU Stock Crashed 68%, But It’s Not A New Offering – Retail Traders Call It An ‘Overreaction’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

On Monday, Deutsche Bank said CAR’s downgrade to ‘Hold’ from ‘Buy' is "purely fundamental in nature"

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.33
Prev Close	$4.77
Open	$4.60
Dividend Yield	0.00%
50-Day Moving Average	$5.35
Beta	1.12
Avg. Volume	4,644.71
PE Ratio	-0.20

52-Week High	$10.54
52-Week Low	$1.90
Market Capitalization	$6.97M
EPS (Annual)	-$35.75
Price to Book	0.38
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

CNSP Fundamentals